Vilon
Lys-Glu dipeptide from the Khavinson ecosystem; limited regional evidence.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Vilon (Lys-Glu) is one of the most cited dipeptides within the Khavinson thymic/geroprotective package. It appears in reviews on gene regulation by peptides; certainty for a Western consumer remains low.
Studied for
How it works
Proposed: interaction with the genome/epigenetics of immune cells. Limited independent details.
What the research says
Included in PMC8619776 reviews and regional clinical bioregulator literature.
Evidence level
D–C regional
What's most reported
- Immune/gerontological parameters in the group's series
- Longevity community: “immune age” — not validated
Common side effects
Not well-characterized outside of the group's literature.
Combines / does not combine
Avoid baseless bioregulator polypharmacy.
Frequently asked questions
No; it is a dipeptide from a regional research tradition.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidance. Research products are not approved drugs unless otherwise stated.